Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6124 -0.0046 (-0.75%)
Streaming Delayed Price Updated: 11:37 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Via ACCESS Newswire
News headline image
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Via ACCESS Newswire
News headline image
Lexaria Attending BIO International Convention
Via ACCESS Newswire
News headline image
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Via ACCESS Newswire
News headline image
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Via ACCESS Newswire
News headline image
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Via ACCESS Newswire
News headline image
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Via ACCESS Newswire
News headline image
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Via ACCESS Newswire
News headline image
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
News headline image
Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Friday. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
News headline image
Lexaria Bioscience Earnings Analysis: Q1 Recap ↗
 
Via Benzinga
News headline image
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
News headline image
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE
News headline image
Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
News headline image
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Via ACCESS Newswire
News headline image
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
News headline image
Lexaria's Human GLP-1 Study #5 Begins Dosing
Via ACCESS Newswire
News headline image
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Via ACCESS Newswire
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
News headline image
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.